Hum Genet. 2022 Jan 17; doi: 10.1007/s00439-021-02427-4. Epub 2022 Jan 17.

Biochemical analysis of novel NAA10 variants suggests distinct pathogenic mechanisms involving impaired protein N-terminal acetylation.

Human genetics

Nina McTiernan, Lisbeth Tranebjærg, Anna S Bjørheim, Jacob S Hogue, William G Wilson, Berkley Schmidt, Melissa M Boerrigter, Maja L Nybo, Marie F Smeland, Zeynep Tümer, Thomas Arnesen

PMID: 35039925 DOI: 10.1007/s00439-021-02427-4

Abstract

NAA10 is the catalytic subunit of the N-terminal acetyltransferase complex, NatA, which is responsible for N-terminal acetylation of nearly half the human proteome. Since 2011, at least 21 different NAA10 missense variants have been reported as pathogenic in humans. The clinical features associated with this X-linked condition vary, but commonly described features include developmental delay, intellectual disability, cardiac anomalies, brain abnormalities, facial dysmorphism and/or visual impairment. Here, we present eight individuals from five families with five different de novo or inherited NAA10 variants. In order to determine their pathogenicity, we have performed biochemical characterisation of the four novel variants c.16G>C p.(A6P), c.235C>T p.(R79C), c.386A>C p.(Q129P) and c.469G>A p.(E157K). Additionally, we clinically describe one new case with a previously identified pathogenic variant, c.384T>G p.(F128L). Our study provides important insight into how different NAA10 missense variants impact distinct biochemical functions of NAA10 involving the ability of NAA10 to perform N-terminal acetylation. These investigations may partially explain the phenotypic variability in affected individuals and emphasise the complexity of the cellular pathways downstream of NAA10.

© 2022. The Author(s).

References

1. Afrin A, Prokop JW, Underwood A, Uhl KL, VanSickle EA, Baruwal R, Wajda M, Rajasekaran S, Bupp C (2020) NAA10 variant in 38-week-gestation male patient: a case study. Cold Spring Harb Mol Case Stud 6:a005868 - PubMed
2. Aksnes H, Ree R, Arnesen T (2019) Co-translational, post-translational, and non-catalytic roles of N-terminal acetyltransferases. Mol Cell 73:1097–1114 - PubMed
3. Arnesen T, Anderson D, Baldersheim C, Lanotte M, Varhaug JE, Lillehaug JR (2005) Identification and characterization of the human ARD1-NATH protein acetyltransferase complex. Biochem J 386:433–443 - PubMed
4. Arnesen T, Van Damme P, Polevoda B, Helsens K, Evjenth R, Colaert N, Varhaug JE, Vandekerckhove J, Lillehaug JR, Sherman F et al (2009) Proteomics analyses reveal the evolutionary conservation and divergence of N-terminal acetyltransferases from yeast and humans. Proc Natl Acad Sci USA 106:8157–8162 - PubMed
5. Bader I, McTiernan N, Darbakk C, Boltshauser E, Ree R, Ebner S, Mayr JA, Arnesen T (2020) Severe syndromic ID and skewed X-inactivation in a girl with NAA10 dysfunction and a novel heterozygous de novo NAA10 p.(His16Pro) variant - a case report. BMC Med Genet 21:153 - PubMed
6. Casey JP, Støve SI, McGorrian C, Galvin J, Blenski M, Dunne A, Ennis S, Brett F, King MD, Arnesen T et al (2015) NAA10 mutation causing a novel intellectual disability syndrome with Long QT due to N-terminal acetyltransferase impairment. Sci Rep 5:16022 - PubMed
7. Cheng H, Gottlieb L, Marchi E, Kleyner R, Bhardwaj P, Rope AF, Rosenheck S, Moutton S, Philippe C, Eyaid W et al (2019) Phenotypic and biochemical analysis of an international cohort of individuals with variants in NAA10 and NAA15. Hum Mol Genet 28:2900–2919 - PubMed
8. Drazic A, Arnesen T (2017) [(14)C]-acetyl-coenzyme a-based in vitro N-terminal acetylation assay. Methods Mol Biol 1574:1–8 - PubMed
9. Esmailpour T, Riazifar H, Liu L, Donkervoort S, Huang VH, Madaan S, Shoucri BM, Busch A, Wu J, Towbin A et al (2014) A splice donor mutation in results in the dysregulation of the retinoic acid signalling pathway and causes Lenz microphthalmia syndrome. J Med Genet 51:185–196 - PubMed
10. Gogoll L, Steindl K, Joset P, Zweier M, Baumer A, Gerth-Kahlert C, Tutschek B, Rauch A (2021) Confirmation of Ogden syndrome as an X-linked recessive fatal disorder due to a recurrent NAA10 variant and review of the literature. Am J Med Genet A 185:2546–2560 - PubMed
11. Gottlieb L, Marmorstein R (2018) Structure of human NatA and its regulation by the huntingtin interacting protein HYPK. Structure 26:925-935.e928 - PubMed
12. Johnston JJ, Williamson KA, Chou CM, Sapp JC, Ansari M, Chapman HM, Cooper DN, Dabir T, Dudley JN, Holt RJ et al (2019) NAA10 polyadenylation signal variants cause syndromic microphthalmia. J Med Genet 56:444–452 - PubMed
13. Kalvik TV, Arnesen T (2013) Protein N-terminal acetyltransferases in cancer. Oncogene 32:269–276 - PubMed
14. Kim SM, Ha E, Kim J, Cho C, Shin S-J, Seo JH (2020) NAA10 as a new prognostic marker for cancer progression. Int J Mol Sci 21:8010 - PubMed
15. Landrum MJ, Lee JM, Benson M, Brown GR, Chao C, Chitipiralla S, Gu B, Hart J, Hoffman D, Jang W et al (2018) ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res 46:D1062-d1067 - PubMed
16. Lee C-F, Ou DSc, Lee S-B, Chang L-H, Lin R-K, Li Y-S, Upadhyay AK, Cheng X, Wang Y-C, Hsu H-S et al (2010) HNaa10p contributes to tumorigenesis by facilitating DNMT1-mediated tumor suppressor gene silencing. J Clin Investig 120:2920–2930 - PubMed
17. Lee C-C, Peng S-H, Shen L, Lee C-F, Du T-H, Kang M-L, Xu G-L, Upadhyay AK, Cheng X, Yan Y-T et al (2017) The role of N-α-acetyltransferase 10 protein in DNA methylation and genomic imprinting. Mol Cell 68:89-103.e107 - PubMed
18. Lim J-H, Park J-W, Chun Y-S (2006) Human arrest defective 1 acetylates and activates beta-catenin, promoting lung cancer cell proliferation. Cancer Res 66:10677–10682 - PubMed
19. Liszczak G, Goldberg JM, Foyn H, Petersson EJ, Arnesen T, Marmorstein R (2013) Molecular basis for N-terminal acetylation by the heterodimeric NatA complex. Nat Struct Mol Biol 20:1098–1105 - PubMed
20. Magin RS, March ZM, Marmorstein R (2016) The N-terminal acetyltransferase Naa10/ARD1 does not acetylate lysine residues. J Biol Chem 291:5270–5277 - PubMed
21. Maini I, Caraffi SG, Peluso F, Valeri L, Nicoli D, Laurie S, Baldo C, Zuffardi O, Garavelli L (2021) Clinical manifestations in a girl with NAA10-related syndrome and genotype-phenotype correlation in females. Genes 12:900 - PubMed
22. Målen H, Lillehaug JR, Arnesen T (2009) The protein Nalpha-terminal acetyltransferase hNaa10p (hArd1) is phosphorylated in HEK293 cells. BMC Res Notes 2:32 - PubMed
23. McTiernan N, Støve SI, Aukrust I, Mårli MT, Myklebust LM, Houge G, Arnesen T (2018) NAA10 dysfunction with normal NatA-complex activity in a girl with non-syndromic ID and a de novo NAA10 p.(V111G) variant – a case report. BMC Med Genet 19:47 - PubMed
24. McTiernan N, Darbakk C, Ree R, Arnesen T (2020) NAA10 p.(D10G) and NAA10 p.(L11R) variants hamper formation of the NatA N-terminal acetyltransferase complex. Int J Mol Sci 21:8973 - PubMed
25. McTiernan N, Gill H, Prada CE, Pachajoa H, Lores J, Arnesen T, C study (2021) NAA10 p. (N101K) disrupts N-terminal acetyltransferase complex NatA and is associated with developmental delay and hemihypertrophy. Eur J Hum Genet 29:280–288 - PubMed
26. Mullen JR, Kayne PS, Moerschell RP, Tsunasawa S, Gribskov M, Colavito-Shepanski M, Grunstein M, Sherman F, Sternglanz R (1989) Identification and characterization of genes and mutants for an N-terminal acetyltransferase from yeast. EMBO J 8:2067–2075 - PubMed
27. Myklebust LM, Van Damme P, Støve SI, Dörfel MJ, Abboud A, Kalvik TV, Grauffel C, Jonckheere V, Wu Y, Swensen J et al (2015) Biochemical and cellular analysis of Ogden syndrome reveals downstream Nt-acetylation defects. Hum Mol Genet 24:1956–1976 - PubMed
28. Park EC, Szostak JW (1992) ARD1 and NAT1 proteins form a complex that has N-terminal acetyltransferase activity. EMBO J 11:2087–2093 - PubMed
29. Popp B, Støve SI, Endele S, Myklebust LM, Hoyer J, Sticht H, Azzarello-Burri S, Rauch A, Arnesen T, Reis A (2015) De novo missense mutations in the NAA10 gene cause severe non-syndromic developmental delay in males and females. Eur J Hum Genet 23:602–609 - PubMed
30. Ree R, Geithus AS, Tørring PM, Sørensen KP, Damkjær M, Lynch SA, Arnesen T, DDD study (2019) A novel NAA10 p.(R83H) variant with impaired acetyltransferase activity identified in two boys with ID and microcephaly. BMC Med Genet 20:101 - PubMed
31. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E et al (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17:405–424 - PubMed
32. Rope AF, Wang K, Evjenth R, Xing J, Johnston JJ, Swensen JJ, Johnson WE, Moore B, Huff CD, Bird LM et al (2011) Using VAAST to identify an X-linked disorder resulting in lethality in male infants due to N-terminal acetyltransferase deficiency. Am J Hum Genet 89:28–43 - PubMed
33. Saunier C, Støve SI, Popp B, Gérard B, Blenski M, Ahmew N, Bie C, Goldenberg P, Isidor B, Keren B et al (2016) Expanding the phenotype associated with NAA10-related N-terminal acetylation deficiency. Hum Mutat 37:755–764 - PubMed
34. Seo JH, Park J-H, Lee EJ, Vo TTL, Choi H, Kim JY, Jang JK, Wee H-J, Lee HS, Jang SH et al (2016) ARD1-mediated Hsp70 acetylation balances stress-induced protein refolding and degradation. Nat Commun 7:12882 - PubMed
35. Shin DH, Chun Y-S, Lee K-H, Shin H-W, Park J-W (2009) Arrest defective-1 controls tumor cell behavior by acetylating myosin light chain kinase. PLoS One 4:e7451 - PubMed
36. Sievers F, Wilm A, Dineen D, Gibson TJ, Karplus K, Li W, Lopez R, McWilliam H, Remmert M, Söding J et al (2011) Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol Syst Biol 7:539 - PubMed
37. Støve SI, Blenski M, Stray-Pedersen A, Wierenga KJ, Jhangiani SN, Akdemir ZC, Crawford D, McTiernan N, Myklebust LM, Purcarin G et al (2018) A novel NAA10 variant with impaired acetyltransferase activity causes developmental delay, intellectual disability, and hypertrophic cardiomyopathy. Eur J Hum Genet 26:1294–1305 - PubMed
38. Van Damme P, Evjenth R, Foyn H, Demeyer K, De Bock P-J, Lillehaug JR, Vandekerckhove J, Arnesen T, Gevaert K (2011) Proteome-derived peptide libraries allow detailed analysis of the substrate specificities of N(alpha)-acetyltransferases and point to hNaa10p as the post-translational actin N(alpha)-acetyltransferase. Mol Cell Proteomics 10:M110.004580 - PubMed
39. Vo TTL, Park J-H, Seo JH, Lee EJ, Choi H, Bae S-J, Le H, An S, Lee HS, Wee H-J et al (2017) ARD1-mediated aurora kinase A acetylation promotes cell proliferation and migration. Oncotarget 8:57216–57230 - PubMed
40. Waterhouse AM, Procter JB, Martin DMA, Clamp M, Barton GJ (2009) Jalview Version 2—a multiple sequence alignment editor and analysis workbench. Bioinformatics 25:1189–1191 - PubMed
41. Wu Y, Lyon GJ (2018) NAA10-related syndrome. Exp Mol Med 50:85 - PubMed
42. Yoon H, Kim H-L, Chun Y-S, Shin DH, Lee K-H, Shin CS, Lee DY, Kim H-H, Lee ZH, Ryoo H-M et al (2014) NAA10 controls osteoblast differentiation and bone formation as a feedback regulator of Runx2. Nat Commun 5:5176 - PubMed

Publication Types

• Journal Article

Grant support

• 249843/Norges Forskningsråd
• 171752-PR-2009-0222/Kreftforeningen
• F-12540/Helse Vest